Sebastian Salentin
Sebastian Salentin
Email verificata su
Citata da
Citata da
PLIP: fully automated protein–ligand interaction profiler
S Salentin, S Schreiber, VJ Haupt, MF Adasme, M Schroeder
Nucleic acids research 43 (W1), W443-W447, 2015
PLIP 2021: Expanding the scope of the protein–ligand interaction profiler to DNA and RNA
MF Adasme, KL Linnemann, SN Bolz, F Kaiser, S Salentin, VJ Haupt, ...
Nucleic acids research 49 (W1), W530-W534, 2021
Current and future roles of artificial intelligence in medicinal chemistry synthesis
TJ Struble, JC Alvarez, SP Brown, M Chytil, J Cisar, RL DesJarlais, ...
Journal of medicinal chemistry 63 (16), 8667-8682, 2020
Polypharmacology rescored: Protein–ligand interaction profiles for remote binding site similarity assessment
S Salentin, VJ Haupt, S Daminelli, M Schroeder
Progress in biophysics and molecular biology 116 (2-3), 174-186, 2014
UniLectin3D, a database of carbohydrate binding proteins with curated information on 3D structures and interacting ligands
F Bonnardel, J Mariethoz, S Salentin, X Robin, M Schroeder, S Perez, ...
Nucleic acids research 47 (D1), D1236-D1244, 2019
From malaria to cancer: Computational drug repositioning of amodiaquine using PLIP interaction patterns
S Salentin, MF Adasme, JC Heinrich, VJ Haupt, S Daminelli, Y Zhang, ...
Scientific reports 7 (1), 11401, 2017
The structural basis of the genetic code: amino acid recognition by aminoacyl-tRNA synthetases
F Kaiser, S Krautwurst, S Salentin, VJ Haupt, C Leberecht, S Bittrich, ...
Scientific Reports 10 (1), 12647, 2020
Discovery of Mycobacterium tuberculosis InhA Inhibitors by Binding Sites Comparison and Ligands Prediction
T Štular, S Lešnik, K Rožman, J Schink, M Zdouc, A Ghysels, F Liu, ...
Journal of medicinal chemistry 59 (24), 11069-11078, 2016
Repositioned drugs for chagas disease unveiled via structure-based drug repositioning
MF Adasme, SN Bolz, L Adelmann, S Salentin, VJ Haupt, ...
International Journal of Molecular Sciences 21 (22), 8809, 2020
Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor
MF Adasme, D Parisi, K Van Belle, S Salentin, VJ Haupt, GS Jennings, ...
PLoS One 15 (5), e0233089, 2020
Computational drug repositioning for chagas disease using protein-ligand interaction profiling
A Jurez-Saldivar, M Schroeder, S Salentin, VJ Haupt, E Saavedra, ...
International journal of molecular sciences 21 (12), 4270, 2020
Backbone brackets and arginine tweezers delineate class I and class II aminoacyl tRNA synthetases
F Kaiser, S Bittrich, S Salentin, C Leberecht, VJ Haupt, S Krautwurst, ...
PLoS computational biology 14 (4), e1006101, 2018
Computational drug repositioning by target hopping: A use case in chagas disease
V Joachim Haupt, J E Aguilar Uvalle, S Salentin, S Daminelli, F Leonhardt, ...
Current Pharmaceutical Design 22 (21), 3124-3134, 2016
Structural binding site comparisons reveal Crizotinib as a novel LRRK2 inhibitor
SN Bolz, S Salentin, G Jennings, VJ Haupt, J Sterneckert, M Schroeder
Computational and Structural Biotechnology Journal 19, 3674-3681, 2021
MAGPIE: Simplifying access and execution of computational models in the life sciences
C Baldow, S Salentin, M Schroeder, I Roeder, I Glauche
PLoS computational biology 13 (12), e1005898, 2017
Characterization of Amino Acid Recognition in Aminoacyl-tRNA Synthetases
F Kaiser, S Krautwurst, S Salentin, VJ Haupt, C Leberecht, S Bittrich, ...
BioRxiv, 606459, 2019
In Silico Identification of Novel Cancer Drugs with 3D Interaction Profiling
S Salentin
Technische Universitt Dresden, 2017
One Step further towards Molecular Evolution: Structural Analysis of Class II Aminoacyl tRNA Synthetases
S Krautwurst, C Leberecht, S Bittrich, S Salentin, F Kaiser, VJ Haupt, ...
Binding Mode Characterization of Class II Aminoacyl tRNA Synthetases
F Kaiser, S Salentin, S Bittrich, C Leberecht, V Joachim, MS Haupt, ...
Il sistema al momento non pu eseguire l'operazione. Riprova pi tardi.
Articoli 1–19